New Data From Conviva Reveals Global Spike in Streaming During First Quarter 2021; Viewers Flocking to Big Screens
29.4.2021 16:00:00 EEST | Business Wire | Press release
Conviva, the intelligence cloud for streaming media, released its State of Streaming report for Q1 2021 today, revealing streaming viewing time grew 36% during the first quarter. While North America, the world’s biggest streaming market, saw solid 18% year-over-year growth in streaming viewing, the true streaming explosion occurred internationally, with South America (240%), Africa (149%) and Europe (122%) experiencing triple-digit streaming growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005301/en/
Conviva's State of Streaming Report - Q1 2021 (Graphic: Business Wire)
The report also revealed consumers are flocking to connected TV devices, smart TVs and gaming consoles, as evidenced in big screens commanding 73% share of Q1 streaming viewing globally. Roku and Amazon Fire TV, while still dominant, saw a slight decline (2.9% and 3.6% respectively) in share of viewing time in Q1, as international viewing and smart TVs continued to surge globally. While Roku captured a significant 30% share of global big screen viewing time, this dominance was primarily driven by North America where it commanded 37% share in Q1 2021. In Europe, the second largest market for Roku, Roku only accounted for 8% share of the big screen, and it did not fare any better in other regions, with 4% share or less in Africa, Asia, Oceania, and South America.
“In every region in the world, streaming viewership is growing, representing a global shift in the way people consume content,” said Bill Demas, CEO, Conviva. “This rapidly expanding international audience has created an enormous opportunity for content developers, device manufacturers and advertisers to engage new audiences as the brands and publishers who understand exactly how, when and where people are streaming, will inevitably triumph.”
Streaming Viewing Grows Globally; Varies by Region
According to Conviva’s findings, there is significant variation in the way consumers in different regions stream on big screens. In Africa, where big screens represent 56% of all viewing time, CanalPlus set top box was the preferred device, with 54% share of all Q1 big screen viewing time. In Asia, Android TV held 49% of all Q1 big screen viewing time, while in North America, where big screens are responsible for 81% of all viewing time, Roku continued to dominate with 37% share. In Europe, big screen viewing time was divided relatively equally among devices, while in Oceania, Chromecast ruled with 24% and in South America, Samsung TV held 30% share of big screen viewing.
Streaming Ads Surge and Improve; Super Bowl Pays Dividends
Q1 2021 saw a post-pandemic resurgence of streaming ads, with ad attempts growing 4%, ad impressions jumping 13% and missed ad opportunities falling 16% quarter over quarter. Ad quality also improved in Q1 2021 with ad start times down to half a second, a 50% improvement, and bitrates up 57% as compared to Q4 2020. Conviva also found advertisers experienced significant ROI from their Super Bowl efforts, sustaining nearly three times the level of social engagement post-Super Bowl as compared to pre-Super Bowl.
Streaming Publishers Find Success on Social
Social platforms continue to deliver strong ROI for streaming publishers, delivering new audiences and increased engagement. The total number of posts from streaming publishers on Facebook, Instagram, Twitter and YouTube combined grew 99% in Q1 2021 as compared to Q1 2020, with total videos increasing 39% and total engagements increasing 24%. Audience growth across all social platforms, including Facebook, Instagram, Twitter, YouTube and TikTok, grew 61% year over year.
To learn more visit: www.conviva.com/state-of-streaming
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with 1.5 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 900 accounts, over 1.8 million posts, 910 thousand videos, 6 billion video views, and over 35 billion engagements across Facebook, Instagram, TikTok, Twitter, and YouTube.
About Conviva
Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and StreamID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005301/en/
Contact information
Paula Winkel
pr@conviva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
